Non-steroidal anti-inflammatory drugs (NSAIDs) remain the principal pharmacological agents for symptom relief in patients with the rheumatic diseases. Host-guest chemistry, the basis of piroxicam β-cyklodekstrin (PBC) began to receive widespread attention following the award of the 1987 Nobel chemistry prize to Cram, Pederson and Lehn. β-cyklodekstrin is a soluble cyclic oligosaccharide that is able to modify the pharmacokinetics of various substances. The inclusion of piroxicam in β-cyklodekstrin increased the water solubility and rate of absorption of the drug without altering its clinical effects. Result of clinical trials shows that PBC is effective and well tolerated in the treatment of patients with acute and chronic pain. However when we use NSAIDs we should consider the clinical effects and potentially adverse events.